Stock vs Stock Comparison

Beam Therapeutics Inc. vs AbbVie Inc.

ABBV wins the Tale of the Tape 6–3.

BEAM$28.96
ABBV$215.40

🏆 Tale of the Tape

36
BEAMABBV
-57.2%Profitability (Net Margin)6.9%
Valuation (P/E)106.2x
-21.9%Efficiency (ROIC)8.3%
3/9Health (Piotroski F)7/9
5.5Safety (Altman Z)2.0
120.0%Growth (Rev YoY)8.6%
1.12Risk (Sharpe 1Y)0.61
0.20xBalance Sheet (D/E)-42.50x
-14.41%FCF Yield4.23%

Green = winner in each category. Higher is better except P/E (lower = cheaper).

Rolling Correlation

0.261
252-Day Correlation
0.215
126-Day Correlation

Low correlation — excellent diversification pair.

Fundamentals

MetricBEAMABBV
Market Cap$3.4B$384.7B
P/E Ratio106.2x
Forward P/E-6.9x13.4x
P/B2.81x-57.80x
Dividend Yield3.18%
Beta2.260.30

Quantitative Metrics

MetricBEAMABBV
DCF Fair Value$126.26
DCF Upside-38.9%
Piotroski F3/97/9
Altman Z5.542.01
Beneish M-2.87
FCF Yield-14.41%4.23%
Net Debt/EBITDA3.0x
ROIC-21.9%8.3%
WACC7.4%
ROIC – WACC0.8pp
Gross Margin70.2%
Net Margin-57.2%6.9%
Rev Growth YoY120.0%8.6%
Sharpe (1Y)1.120.61
Max Drawdown 3Y-67.7%
FCF Payout Ratio65%

BEAM Price

Loading chart...

ABBV Price

Loading chart...

ETF Exposure

BEAM found in:

ARKG4.83%
ARKK2.76%
XBI1.23%
VBK0.09%
VTWO0.09%
VHT0.04%

ABBV found in:

XLV7.07%
IYH6.86%
VHT6.04%
HDV5.61%
SCHD3.53%
DGRO2.52%
DGRW1.99%
MGV1.85%
VIG1.68%
VYM1.56%
NOBL1.49%
VTV1.46%
SDY1.42%
IWF1.39%
SCHV1.38%
VONG1.21%
XBI1.09%
ESGV0.78%
SPYV0.71%
IVV0.69%
SPLG0.68%
SCHX0.66%
SCHB0.62%
ITOT0.61%
VOO0.60%
SPY0.59%
VONE0.57%
SPTM0.55%
VTI0.54%
SPYG0.50%
URTH0.48%
ACWI0.41%
VFVA0.41%
VT0.33%
QUS0.32%
VFMV0.25%
RSP0.19%
ONEO0.03%

More Comparisons

Quant metrics computed from financial statements and 1,200+ trading days. Correlation is Pearson coefficient on daily log returns. Not investment advice.

BEAM vs ABBV: Head-to-Head Analysis

Beam Therapeutics Inc. (BEAM) and AbbVie Inc. (ABBV) represent two companies in the Healthcare sector. In our quantitative Tale of the Tape scoring, ABBV leads 6–3 across nine fundamental and risk metrics including profitability, valuation, capital efficiency, and financial health.

In terms of capital efficiency, BEAM generates a return on invested capital (ROIC) of -21.9% compared to ABBV's 8.3%. This suggests ABBV is more effective at deploying capital to generate shareholder returns.

The 252-day rolling correlation between BEAM and ABBV is 0.261, indicating low correlation, making them an effective diversification pair in a portfolio context.

BEAM appears in 6 ETFs tracked by SecuritiesDB, while ABBV appears in 38 ETFs. Investors holding broad-market ETFs may already have indirect exposure to both stocks.

Frequently Asked Questions

Which stock is the better investment, BEAM or ABBV?

Our quantitative analysis compares BEAM and ABBV across nine fundamental dimensions. ABBV wins the Tale of the Tape 6–3. However, stock selection depends on your individual risk tolerance, time horizon, and portfolio context. These metrics are computed from SEC filings and market data — they are not investment recommendations.

Are BEAM and ABBV correlated?

The 252-day correlation between BEAM and ABBV is 0.261. They have low correlation, offering good diversification.

How is the Tale of the Tape scored?

The Tale of the Tape compares both stocks across nine categories: profitability (net margin), valuation (P/E), efficiency (ROIC), health (Piotroski F-Score), safety (Altman Z-Score), growth (revenue YoY), risk (Sharpe ratio), leverage (debt-to-equity), and cash generation (FCF yield). The stock that wins more categories takes the overall score. Lower P/E and lower debt-to-equity count as wins.